Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'

Pfizer Inc (NYSE:PFE) reported first-quarter earnings Wednesday with adjusted EPS of 82 cents. That's down 33% year-over-year, beating the consensus of 54 cents.The New York-based company witnessed a

Benzinga18minutes ago

Palatin Spikes as FDA Clears Mid-stage Trial for Weight Loss Therapy

Seeking Alpha24minutes ago

Express News | Regeneron Shares Are Trading Higher, Reversing After Earlier Dropping on a Q1 Earnings Miss

Benzinga29minutes ago

Express News | Needham Reiterates Buy on Geron, Maintains $5 Price Target

Benzinga51minutes ago

Geron Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 26.26% Needham → $5 Reiterates Buy → Buy 04/30/2024 13.64% Baird → $4.5 Downgrades Outperform →

Benzinga52minutes ago

Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal

Seeking Alpha14:31 ET